- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05067764
Efficacy of Aponeurectomy on the 2-year Recurrence Rate of Dupuytren's Disease (REMEDY)
Multicenter, Randomized, Open-label Study Evaluating the Efficacy of Aponeurectomy Associated With Adipose Tissue Grafting Compared to Aponeurectomy Alone, on the 2-year Recurrence Rate of Dupuytren's Disease (REMEDY).
Dupuytren's disease is a frequent hereditary disease in Northern Europe. It is a degenerative disease affecting the palmar aponeurosis of the hand. It develops a progressive contractile fibrosis which cuts the hypodermic fatty tissue, adheres to the skin and the phalanges, gradually bending the affected rays, resulting in significant functional impotence.
Various medical and surgical treatments are available.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Among these treatments, none to date can eliminate recurrences, which are still too frequent.
Open aponeurectomy (consisting of surgical curettage of the fibrotic cords) remains for the moment the reference technique for treating Dupuytren's disease, with recurrences (between 12 and 39%), but less frequent than the needle technique (50 to 85%).
Could the addition of adipose tissue in the resection areas of Dupytren's fibrosis reduce the rate of recurrence (by the inhibitory action of ADCs on myofibroblasts) in addition to reconstructing the hypodermis in the cavity left by the resection of the cords and improving the quality of the scars? The investigators insist on the fact that this is a homotopic and homologous adipose tissue graft, in closed circuit without denaturation or adjuvant products.
Since, to our knowledge, no other team has used "lipofilling" as an adjuvant treatment to the open resection technique of Dupuytren's cords (aponeurectomy), the investigators first conducted a clinical feasibility and safety study on 70 patients between 2012 and 2017 (currently being published by Springer Editions).
The investigators now wish to conduct a prospective comparative study between patients operated by aponeurectomy WITH (experimental group) and WITHOUT (control group) addition of autologous adipose tissue in the resection areas of Dupuytren's cords.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Elias Sawaya, MD
- Phone Number: +33 (0)663420278
- Email: esawaya.md@gmail.com
Study Locations
-
-
-
Mulhouse, France, 68100
- Not yet recruiting
- Clinique du Diaconat
-
Contact:
- Chihab TALEB, MD
- Phone Number: 03 89 70 34 70
-
Pessac, France, 33600
- Recruiting
- Institut Aquitain de la Main
-
Contact:
- Elias Sawaya, MD
- Phone Number: +33 (0)663420278
- Email: esawaya.md@gmail.com
-
Contact:
- Charlène PY, CRA
- Email: charlene.py@elsan.care
-
Principal Investigator:
- Elias Sawaya, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 years
- Carrier of Tubiana stage II-IV Dupuytren's disease on at least one or more rays, not previously operated
- Indication of a surgery by aponeurectomy
- Skin pinch of the posterior aspect of the arm of more than 1cm
- Affiliation to a social security system
- Patient informed of the study and having given informed consent
Exclusion Criteria:
- Previous surgery of any kind for Dupuytren's disease
- Involvement on the thumb only
- Need for a total skin graft or a pedicle flap on all the rays to be treated
- Active autoimmune disease
- Previous treatment with collagenase
- Pregnant and breastfeeding women
- Patient under legal protection
- Contraindications to MRI (criteria applicable only for patients from the coordinating center, not applicable for other centers)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Aponeurectomy with grafting
The experimental group evaluates the aponeurectomy associated with adipose tissue grafting.
|
The lipofilling is performed, once the incisions are closed and is performed with the Puregraft® system. The fat graft is taken from the posterior, medial and anterior sides of the arm, by skin puncture. Approximately 10 cc are harvested, allowing a reinjection of about 2 cc per digital radius treated. After conditioning, the fat graft is redistributed to the curettage areas through the skin incisions. |
Active Comparator: Aponeurectomy alone
The control group evaluates the aponeurectomy alone.
|
The patient is installed in dorsal decubitus position and the arm to be treated is anesthetized by axillary block.
The procedure is performed in the operating room, respecting all the rules of asepsis and safety in force.
A tourniquet is placed on the arm to be treated and inflated to 250mmHg.
Broken incisions are then made opposite the cords to be excised, which are located by palpation.
Once the noble elements have been identified, the excision of the cords and fibrous nodules can be done as completely as possible.
Sometimes an arthrolysis procedure is necessary in order to restore extension to a joint that has been fixed in a flexion position for several years.
Skin closure is most often possible by direct suture or by means of local fatty skin flaps.
In some cases, the surgeon may use total skin grafts, or directed healing in certain areas where direct skin suture is not possible.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
2-year recurrence rate of Dupuytren's disease
Time Frame: 2 Years after intervention
|
Recurrence being defined as follows: appearance, at 2 years post-op compared to 6 weeks post-op, of a contracture of more than 20 degrees, with palpable cord, on any treated joint.
|
2 Years after intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
3-year recurrence rate in both groups
Time Frame: 3 Years after intervention
|
Recurrence being defined as follows: Appearance of a contracture of more than 20 degrees, with palpable cord, on any treated joint, at 3 years post-op compared to 6 weeks post-op
|
3 Years after intervention
|
5-year recurrence rate in both groups
Time Frame: 5 Years after intervention
|
Recurrence being defined as follows: Appearance of a contracture of more than 20 degrees, with palpable cord, on any treated joint, at 5 years post-op compared to 6 weeks post-op
|
5 Years after intervention
|
Comparison of the appearance of scars in both groups
Time Frame: 1 Year after intervention
|
Use of questionnaire The Patient and Observer Scar Assessment Scale (POSAS).
This questionnaire consists of 2 separate scales of 6 items each (one scale for the observer and one scale for the patient).
Each item is evaluated on 10 points.
The lowest score is "1" which corresponds to the appearance of normal skin.
A score of 10 indicates the greatest deviation from normal skin.
The total score for each of the scales is obtained by adding the score for each of the 6 items.
This total score can vary between 6 and 60 for each of the scales.
|
1 Year after intervention
|
Comparison of the appearance of scars in both groups
Time Frame: 2 Years after intervention
|
Use of questionnaire The Patient and Observer Scar Assessment Scale (POSAS).
This questionnaire consists of 2 separate scales of 6 items each (one scale for the observer and one scale for the patient).
Each item is evaluated on 10 points.
The lowest score is "1" which corresponds to the appearance of normal skin.
A score of 10 indicates the greatest deviation from normal skin.
The total score for each of the scales is obtained by adding the score for each of the 6 items.
This total score can vary between 6 and 60 for each of the scales.
|
2 Years after intervention
|
Comparison of the complication rates in both groups
Time Frame: 1 Week after intervention
|
Complications are defined as Hematoma, infection, graft lysis, disunion or nerve damage.
|
1 Week after intervention
|
Comparison of the complication rates in both groups
Time Frame: 6 Weeks after intervention
|
Complications are defined as Hematoma, infection, graft lysis, disunion or nerve damage.
|
6 Weeks after intervention
|
Comparison of the rate of occurrence of algodystrophy, regardless of cause
Time Frame: 1 Year after intervention
|
Collection of information on the occurrence of algodystrophy, considered as Adverse Event of Special Interest.
|
1 Year after intervention
|
Comparison of the rate of occurrence of algodystrophy, regardless of cause
Time Frame: 2 Years after intervention
|
Collection of information on the occurrence of algodystrophy, considered as Adverse Event of Special Interest.
|
2 Years after intervention
|
Comparison of the rate of occurrence of algodystrophy, regardless of cause
Time Frame: 3 Years after intervention
|
Collection of information on the occurrence of algodystrophy, considered as Adverse Event of Special Interest.
|
3 Years after intervention
|
Comparison of the rate of occurrence of algodystrophy, regardless of cause
Time Frame: 5 Years after intervention
|
Collection of information on the occurrence of algodystrophy, considered as Adverse Event of Special Interest.
|
5 Years after intervention
|
Evaluation of hypodermic fat volume loss
Time Frame: 1 Year after intervention
|
Measurement of hypodermal fat thickness on MRI for five patients of experimental group, only include in the coordinating center. The evolution is measured with preoperative, immediate postoperative (day of surgery) and 1-year MRI. |
1 Year after intervention
|
Comparison of the effect on quality of life in both groups
Time Frame: 6 Weeks after intervention
|
Use of Quick Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire.
The score consists of 11 questions that assess the function of the upper limb for the gestures of daily life.
The final score is between 0 and 100, with 0 corresponding to normal function, and 100 to almost no function.
|
6 Weeks after intervention
|
Comparison of the effect on quality of life in both groups
Time Frame: 1 Year after intervention
|
Use of Quick Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire.
The score consists of 11 questions that assess the function of the upper limb for the gestures of daily life.
The final score is between 0 and 100, with 0 corresponding to normal function, and 100 to almost no function.
|
1 Year after intervention
|
Comparison of the effect on quality of life in both groups
Time Frame: 2 Years after intervention
|
Use of Quick Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire.
The score consists of 11 questions that assess the function of the upper limb for the gestures of daily life.
The final score is between 0 and 100, with 0 corresponding to normal function, and 100 to almost no function.
|
2 Years after intervention
|
Comparison of the effect on quality of life in both groups
Time Frame: 5 Years after intervention
|
Use of Quick Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire.
The score consists of 11 questions that assess the function of the upper limb for the gestures of daily life.
The final score is between 0 and 100, with 0 corresponding to normal function, and 100 to almost no function.
|
5 Years after intervention
|
Evaluation of the safety of aponectomy surgery associated or not with adipose tissue grafting
Time Frame: 6 Weeks after intervention
|
Collection of adverse events
|
6 Weeks after intervention
|
Evaluation of the primary endpoint on the second hand operated on.
Time Frame: Within five years after intervention
|
The surgery being done with or without fat according to the treatment of the 1st randomized hand (cross-over scheme). Data collection for the second surgery only if it occurs between the 1st hand surgery and the patient's protocol discharge. |
Within five years after intervention
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Elias SAWAYA, MD, Institut Aquitain de la Main
Publications and helpful links
General Publications
- Beaton DE, Wright JG, Katz JN; Upper Extremity Collaborative Group. Development of the QuickDASH: comparison of three item-reduction approaches. J Bone Joint Surg Am. 2005 May;87(5):1038-46. doi: 10.2106/JBJS.D.02060.
- Coleman SR. Structural fat grafting: more than a permanent filler. Plast Reconstr Surg. 2006 Sep;118(3 Suppl):108S-120S. doi: 10.1097/01.prs.0000234610.81672.e7.
- Mintken PE, Glynn P, Cleland JA. Psychometric properties of the shortened disabilities of the Arm, Shoulder, and Hand Questionnaire (QuickDASH) and Numeric Pain Rating Scale in patients with shoulder pain. J Shoulder Elbow Surg. 2009 Nov-Dec;18(6):920-6. doi: 10.1016/j.jse.2008.12.015. Epub 2009 Mar 17.
- Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001 Apr;7(2):211-28. doi: 10.1089/107632701300062859.
- Mojallal A, Lequeux C, Shipkov C, Breton P, Foyatier JL, Braye F, Damour O. Improvement of skin quality after fat grafting: clinical observation and an animal study. Plast Reconstr Surg. 2009 Sep;124(3):765-774. doi: 10.1097/PRS.0b013e3181b17b8f.
- Selles RW, Zhou C, Kan HJ, Wouters RM, van Nieuwenhoven CA, Hovius SER. Percutaneous Aponeurotomy and Lipofilling versus Limited Fasciectomy for Dupuytren's Contracture: 5-Year Results from a Randomized Clinical Trial. Plast Reconstr Surg. 2018 Dec;142(6):1523-1531. doi: 10.1097/PRS.0000000000004982.
- Henry M. Dupuytren's disease: current state of the art. Hand (N Y). 2014 Mar;9(1):1-8. doi: 10.1007/s11552-013-9563-0.
- Engstrand C, Krevers B, Nylander G, Kvist J. Hand function and quality of life before and after fasciectomy for Dupuytren contracture. J Hand Surg Am. 2014 Jul;39(7):1333-1343.e2. doi: 10.1016/j.jhsa.2014.04.029.
- Verhoekx JSN, Mudera V, Walbeehm ET, Hovius SER. Adipose-derived stem cells inhibit the contractile myofibroblast in Dupuytren's disease. Plast Reconstr Surg. 2013 Nov;132(5):1139-1148. doi: 10.1097/PRS.0b013e3182a3bf2b.
- Foucher G, Medina J, Navarro R. Percutaneous needle aponeurotomy: complications and results. J Hand Surg Br. 2003 Oct;28(5):427-31. doi: 10.1016/s0266-7681(03)00013-5.
- Kan HJ, Verrijp FW, Hovius SER, van Nieuwenhoven CA; Dupuytren Delphi Group; Selles RW. Recurrence of Dupuytren's contracture: A consensus-based definition. PLoS One. 2017 May 15;12(5):e0164849. doi: 10.1371/journal.pone.0164849. eCollection 2017. Erratum In: PLoS One. 2019 Apr 25;14(4):e0216313.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- REMEDY
- 2020-A03214-35 (Other Identifier: ANSM)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dupuytren's Disease
-
University of MinnesotaRecruitingDupuytren Contracture | Dupuytren Disease of Finger | Dupuytren's Disease | Dupuytren Disease of Palm and Finger | Dupuytrens Contracture of Both Hands | Dupuytren's Disease of Palm of Right Hand | Dupuytren's Disease of Palm of Left Hand | Dupuytren Contracture of Right Palm | Dupuytren Contracture... and other conditionsUnited States
-
Endo PharmaceuticalsCompletedAdvanced Dupuytren's DiseaseUnited States
-
Endo PharmaceuticalsCompletedAdvanced Dupuytren's DiseaseUnited States
-
Endo PharmaceuticalsCompletedAdvanced Dupuytren's DiseaseAustralia
-
University of CalgaryUnknownDupuytren Contracture | Dupuytren's Disease of FingerCanada
-
Regionshospitalet SilkeborgRecruitingNeoplasms | Neoplasms, Connective and Soft Tissue | Neoplasms by Histologic Type | Joint Diseases | Musculoskeletal Diseases | Connective Tissue Diseases | Neoplasms, Connective Tissue | Fibroma | Contracture | Dupuytren Contracture | Dupuytren's Disease | Neoplasm, Fibrous TissueDenmark
-
Uppsala UniversityRecruitingDupuytren Contracture | Dupuytren's DiseaseSweden
-
Hospital for Special Surgery, New YorkAuxilium Pharmaceuticals, Inc.CompletedDupuytren's DiseaseUnited States
-
Indiana Hand to Shoulder CenterStony Brook UniversityTerminatedDupuytren's DiseaseUnited States
-
Foundation for Orthopaedic Research and EducationEndoPharmceuticalsActive, not recruitingDupuytren Contracture | Dupuytren's DiseaseUnited States
Clinical Trials on Aponeurectomy with grafting
-
The University of Texas Health Science Center,...CompletedAlveolar Ridge Preservation | Extraction Socket HealingUnited States
-
Maastricht University Medical CenterErasmus Medical Center; Academisch Medisch Centrum - Universiteit van Amsterdam... and other collaboratorsRecruitingEvaluating the Utility of Bone Grafts in Open Wedge Corrective Osteotomy and Plate Fixation (WOPPeR)Malunion of Fracture of RadiusNetherlands
-
Cairo UniversityNot yet recruiting
-
University of IowaOsteogenics BiomedicalCompletedAtrophy of Edentulous Alveolar RidgeUnited States
-
University of Alabama at BirminghamCompletedCalcaneus FracturesUnited States
-
University of MichiganOsteogenics BiomedicalEnrolling by invitation
-
Hams Hamed AbdelrahmanCompleted
-
Cairo UniversityCompletedImmediate Implants | Esthetic Zone | Labial Bone Dimensional Changes | Without Labial Bone Grafting | With Labial Grafting | Thin Labial Plate of Bone Pre-extractionEgypt
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
University of Alabama at BirminghamCompletedAlveolar Ridge Preservation | Alveolar Ridge AugmentationUnited States